SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Avantis is the largest RWA perps DEX in DeFi, built on and backed by Base. Avantis allows users to trade crypto and real-world assets (RWAs), including FX, commodities, indices, and equities. Backed by Pantera and Coinbase, Avantis is the largest DEX on Base by volumes, and brings institutional-grade products to DeFi, letting users trade with up to 500x leverage in a transparent, permissionless environment.  Avantis is best known for launching zero-fee perpetuals (ZFP) — a first-of-its-kind primitive where traders only pay fees if they profit. They've also brought leveraged RWAs onchain. This has driven explosive growth: over $20B+ in cumulative volume and 15M+ run-rate revenues since Febrruary 2024.

Avantis

Avantis ($AVNT.X) is trending with community members pointing to recent exchange listings and backing from major players like Peter Thiel and Coinbase. Some users believe $AVNT.X has the potential to reach prices similar to other decentralized exchanges and are drawing comparisons to $MYX.X and $HYPE.X. Traders are actively discussing entry points, potential price targets, and whether to HODL or take profits amid the high volatility.

PHUMPTOM (PHUM) is a meme token, the symbol of which is a phantom. The story of this character is built around trading, and according to legend, he was born on the pump platform.fun from the energy of green candles. Now it is a symbol of green charts, the keeper of green candles. His presence portends growth, and he brings good luck to traders.  A positive character who tells his story like an adventure, generates memes where he always rushes to the aid of traders and gives good luck to holders.

PHUMPTOM

$PHUM.X is trending as users coordinate buys and encourage others to join before a potential breakout, with many sharing links to the token on Phantom. Community members are using terms like 'rocket loading' and 'moon vibes', while also mentioning its connection to other trending tokens. Some users highlight that it is still early to get in.

Orderly Network is a L2 built on OP stack delivering a permissionless liquidity layer for Web3 trading, with one shared orderbook across different blockchains — powered by Orderly Chain and LayerZero. Our mission is to empower trading on any chain, any asset, any interface. Orderly offers spot and perpetual futures orderbooks trading across Arbitrum, Optimism, Polygon, Base ,Mantle and Near, while expanding to other blockchains.

Orderly Network

Orderly Network is trending as the community anticipates potential news this week, fueling speculation of a breakout. Investors are actively discussing accumulation strategies, viewing current levels as buying opportunities. The overall sentiment suggests confidence in the project's potential, with some highlighting its appeal as a promising venture.

LayerAI is the ZK Layer-2 blockchain that powers the AI revolution. $LAI blockchain hosts apps with 2+ million active users, placing it as one of the biggest blockchains at launch.  ZK Layer-2 Blockchain that lets you own the monetisation of your AI data. Turn every task of your daily life into a source of income.  Data is the new holy grail: the asset that powers the AI revolution. Without data, it is not possible to build and improve AI. Big tech - Meta, Google and many others - are built on monetizing user data.  LayerAI is the 1st technology to successfully merge blockchain and AI, built to decentralize the wealth of the trillion-dollar AI & data market.  LayerAI supplies data for AI: a trillion-dollar business ready for decentralization and disruption.  LayerAI is the fastest growing app in human history - It was first to create an AI app that retail can use. But ChatGPT is funded privately - you can’t get a piece of OpenAI's success.  AI projects exploded in growth in recent weeks - but they have a problem: none of them have enough users to reach virality like ChatGPT.  LayerAI already has apps with 2 million users - the only AI platform to come close to ChatGPT's success. Developers of lifestyle, music, gaming, dating, travel & other apps join CryptoGPT’s ecosystem to unlock a new source of data income.  Now is the perfect time for LayerAI to come out of stealth, developing since mid 2022.  LayerAI, like ChatGPT, is aimed at mass retail adoption - in contrast to other blockchain-based AI projects. This opens up an untapped market opportunity: entering the market via consumer apps. Owing to our web3 native marketing channels and value proposition, we have already onboarded applications in gaming, fitness, education, travel and other verticals.  This makes LayerAI the first sustainable ‘to earn’ ecosystem that pays users for contributing data that is then sold in the global data marketplace.  LayerAI is a the layer-2 that is the dedicated blockchain for AI development  Scalable Layer-2: LayerAI is a layer-2 that uses zkRollup technology. The unique EVM- compliance makes the protocol open to massive codebase libraries, enabling easy and rapid onramp of developers and users.  Truly Distributed: LayerAI is carefully designed to be a network uncontrollable by centralized influence. The mining model and security align with the activity. #ProofOfActivity ensures the network’s security increases in parallel to adoption.  Totally Limitless: Immensely scalable, ultra-low-cost transactions combine with empowering infrastructure – data capsules, AI tooling, pluggable earn launcher – to create a blockchain that can expand the abilities of the global economy with the economics of AI.

LayerAI

LayerAI ($LAI.X) is trending as traders discuss recent volatility and potential for a bull run, with some users pointing to a Layer 2 upgrade and new exchange listings as possible catalysts. Community members are actively debating the legitimacy of the project, with conflicting opinions on its future and some reporting issues with trading on certain platforms like Uphold. Discussions also involve the project's connection to XRP and speculation around future price movements.

Pitbull

Pitbull (PIT.X) is trending, with community members highlighting its unique, community-driven structure and recent promotional campaigns. Discussions revolve around its potential in the NFT and Metaverse spaces, as well as its strong community, often referred to as the "Pitbull Army". Some users are celebrating the token trending on certain platforms and anticipating future growth.

Duke Energy Corp. engages in the distribution of natural gas and energy-related services. It operates through the following segments: Electric Utilities and Infrastructure, Gas Utilities and Infrastructure, and Other. The Electric Utilities and Infrastructure segment conducts operations in regulated electric utilities in the Carolinas, Florida and the Midwest. The Gas Utilities and Infrastructure segment focuses on Piedmont, natural gas local distribution companies in Ohio and Kentucky, and natural gas storage and midstream pipeline investments. The Other segment includes interest expense on holding company debt, unallocated corporate costs, and Bison which is a wholly owned captive insurance company. The company was founded on April 30, 1904 and is headquartered in Charlotte, NC.

Duke Energy Corp.

Duke Energy is trending due to discussions around expanding to meet potential demand from AI data centers and renewable energy commitments, highlighted by a recent JP Morgan update. However, concerns about utility sector transition costs, potential dividend cuts, and debt levels are also circulating within the community. Trading strategies involving call options are being actively shared among investors.

First Horizon Corp. (Tennessee) operates as a financial holding company, which engages in the provision of checking accounts, savings products, mortgage banking, lending, and financing to individuals and businesses. It operates the business through three segments: Regional Banking, Specialty Banking, and Corporate. The Regional Banking segment offers financial products and services, including traditional lending and deposit taking, to retail and commercial customers. The Specialty Banking segment consists of lines of business that deliver product offerings and services with specialized industry knowledge. The Corporate segment focuses on corporate support functions such as risk management, audit, accounting, finance, executive office, and corporate communications. The company was founded by Frank S. Davis in 1864 and is headquartered in Memphis, TN.

First Horizon Corporation

First Horizon is trending amid analyst rating adjustments and community discussions around its potential for growth as an independent bank following a terminated merger. Bullish sentiment is fueled by Citigroup and B of A Securities upgrading the stock to a Buy rating. Community members are closely watching resistance levels and potential breakout opportunities, while also considering rising expenses and loan concentration as potential challenges.

The 401jk (just kidding) meme is a satirical punch in the gut in the face of the concept of retirement and also the 401k. The 401k total holdings are valued at around $12 trillion USD and it is the most popular retirement savings plan in the US. As time passes forevermore true retirement, or as we like to call it real freedom will only become much harder and harder for people to attain.  Through meme fueled laser focus and cyperphunk ideology the 401jK meme retirement fund token and community aim to point out the absurdities of how rigged our current system is, and how only insiders and those with power are starting the benefit from the increased centralization of cryptocurrency.........while also aiming to flip the $12 trillion USD 401k system to achieve freedom before our backs and knees are breaking.

401jK

$401JK.X is trending as a meme coin on the Solana network, with the community rallying around its satirical take on traditional retirement plans. The coin's narrative of 'early retirement' and a rejection of the conventional 401k system resonates with investors. Community members express excitement for its potential, citing its strong community and unique concept.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is trending with mixed sentiment as traders debate its potential amid recent developments; some community members express frustration with the price action and question the project's progress, while others remain optimistic, citing upcoming catalysts and long-term potential; discussions also revolve around market dynamics and potential rate cuts.

NEOS ETF Trust - NEOS Bitcoin High Income ETF

NEOS Bitcoin High Income ETF

BTCI is trending as investors discuss its high dividend yield and potential for tax-efficient income through return of capital. Community members are comparing it to other income-generating ETFs and expressing optimism about its ability to track Bitcoin's price movements while providing monthly payouts. The fund's covered call strategy and potential for long-term growth in the crypto space are also key talking points.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Lags Revenue Estimates

CRINETICS PHARM (CRNX) delivered earnings and revenue surprises of -8.85% and -79.78%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Crinetics Pharmaceuticals, Inc. (CRNX) Q2 Earnings Expected to Decline

CRINETICS PHARM (CRNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Retail chatter around Crinetics Pharmaceuticals picked up late Sunday after the company released long-term data for its oral acromegaly drug candidate, Palsonify (paltusotine), showing sustained biochemical control and symptom relief across two Phase 3 studies.At the ENDO 2025 conference, Crinetics shared new data from its ongoing PATHFNDR-1 and PATHFNDR-2 studies, showing that patients who switched from monthly injections to once-daily oral Palsonify were able to keep their insulin-like growth factor 1 (IGF-1) and growth hormone levels steady for nearly two years.&nbsp;Symptom scores, based on the acromegaly symptom diary (ASD), also remained stable. Palsonify was generally well tolerated.In PATHFNDR-2, which studied patients with uncontrolled acromegaly, Palsonify led to sustained reductions in IGF-1 and symptom flares through 84 weeks.&nbsp;Notably, patients who had previously been on placebo experienced meaningful improvements after switching to Palsonify in the open-label extension (OLE).A pooled analysis of symptom scores across both studies showed a significant decrease in day-to-day symptom flares for patients switching from injectables from over 30% of days on somatostatin receptor ligand (SRL) to just 6.2% during stable Palsonify dosing, regardless of baseline control or treatment history.CEO Scott Struthers said the data reinforce Palsonify’s potential as a once-daily, next-generation treatment for acromegaly.&nbsp;Crinetics is also advancing Palsonify in a Phase 3 trial for carcinoid syndrome in patients with neuroendocrine tumors, following promising Phase 2 results in flushing and bowel movement control.In March, the European Medicines Agency (EMA) validated Crinetics' marketing authorization application (MAA) for Palsonify as a long-term maintenance therapy for acromegaly.&nbsp;The EMA had previously granted the drug Orphan Drug Designation in February.&nbsp;On Stocktwits, retail sentiment for Crinetics was ‘bullish’ amid ‘high’ message volume.Crinetics’ stock has declined 38.1% so far in 2025.See also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trumps-35-tariff-threat-ripples-through-walmart-s-bangladesh-supply-chain-report/ch8B1KwR5Np">Trump’s 35% Tariff Threat Ripples Through Walmart’s Bangladesh Supply Chain: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Crinetics Pharmaceuticals' (CRNX) Palsonify (paltusotine) showed sustained biochemical control and symptom relief across two Phase 3 studies. (Photo credit: Getty Images)

Crinetics Pharma’s Oral Drug Shows Lasting Relief For Acromegaly Patients In Latest Study; Retail Buzz Builds

The company presented new data at ENDO 2025 showing that patients who switched from monthly injections to the daily pill maintained hormone control and saw fewer symptom flare-ups over nearly two years. 

Equity

Ionis Pharmaceuticals (IONS) Moves 9.1% Higher: Will This Strength Last?

Ionis Pharmaceuticals (IONS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Futures Drop On DOJ's Google Crackdown, China Plunge

Futures Drop On DOJ's Google Crackdown, China Plunge

 US equity futures are lower on news that the DOJ is considering a breakup of Alphabet's Google search engine, in what would be a...

Strong Future for Crinetics Pharmaceuticals: A Comprehensive Buy Rating Justification

Crinetics Pharmaceuticals (CRNX Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Jonathan W...

XPeng & QuantumScape Are Among Top 11 Mid Cap Stocks That Performed Well Last Week (July 7-July 13): Details

10 mid-cap stocks jumped in last week, including QuantumScape, Lantheus Holdings, Sunrun, Kymera Therapeutics, Apogee Therapeutics, Joby Aviation, Crinetics Pharmaceuticals, Dyne Therapeutics, Summit...

Forecasting The Future: 11 Analyst Projections For Crinetics Pharmaceuticals

Latest Ratings for CRNX
 DateFirmActionFromTo Nov 2021JMP SecuritiesInitiates Coverage OnMarket Outperform Nov 2021Evercore ISI GroupInitiates Coverage OnOutperform Nov 2021HC Wainwright...

17 Analysts Have This To Say About Crinetics Pharmaceuticals

Stanley Druckenmiller Bet On Biotech, Financial Services in Q1, Trimmed Nvidia Stake

Bloomberg / Contributor / Getty Images

 Key TakeawaysBillionaire Stanley Druckenmiller added more than three dozen new positions to his portfolio in the first quarter, including Apple, Reddit...

Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. The firm is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.

Crinetics Pharmaceuticals Inc

Just the one

Three

Four

The Fed just cut rates. How many cuts do you expect in all of 2025? 
 
*Powered by Polymarket

Current Price	$34.30
Prev Close	$35.48
Open	$35.90
Dividend Yield	0.00%
50-Day Moving Average	$31.28
Beta	1.14
Avg. Volume	1.02M
PE Ratio	-8.25

52-Week High	$62.53
52-Week Low	$24.10
Market Capitalization	$3.19B
EPS (Annual)	-$3.69
Price to Book	2.72
Revenue Per Employee	$2,377.57
Enterprise Value/EBITDA	N/A

CRNX
Crinetics Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CRNX News

CRNX Crinetics Pharmaceuticals Inc